The absence of selling and presence of broad-based doubling by mega-passive institutions suggests underlying demand strength. Traders should monitor for follow-through buying and potential inclusion in broader index rebalancing. Given the passive nature of the buyers, this may reflect structural indexing rather than activist conviction, but the scale still supports price stability.
RDY drugs
RDY drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $14.38entry
- T+1 · 9mo ago −0.90%α +0.01% · $14.25
- T+5 · 8mo ago +0.07%α +1.28% · $14.39
- T+20 · 8mo ago −6.40%α +1.54% · $13.46
- T+60 · 6mo ago −4.38%α −13.71% · $13.75
How similar events traded
Executive Summary
Three major passive institutional investors, Morgan Stanley, Wells Fargo, and UBS, significantly increased their positions in Dr. Reddy's Laboratories (RDY) during Q4 2024, collectively doubling their holdings with a net addition of $10.6M in value. Despite the large share count increases, the total current value of holdings rose to $190.2M, indicating strong institutional accumulation. This coordinated activity suggests growing confidence in RDY's stability or valuation, particularly among passive mega-funds.
Key Financial Metrics
Institutional Positions
Net institutional flow: $10.6M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | DOUBLED | +402.2% | $177.8M | -$359.3K |
| UBS | DOUBLED | +4435.2% | $12.3M | $11.0M |
| Wells Fargo | DOUBLED | +495.6% | $124.0K | $19.0K |
Key Facts
- Morgan Stanley increased shares from 2.24M to 11.26M (+402.2%), with value nearly flat at $177.8M
- UBS made the most aggressive move, increasing shares over 44x (17.2K to 780.8K) and value from $1.4M to $12.3M (+$11.0M)
- Wells Fargo doubled down on a small position, adding 6.5K shares with a value increase of $19K
- No institutional selling was observed in this quarter
Financial Impact
3 institutions accumulated $10.6M in net new positions, bringing total tracked holdings to $190.2M
Risk Factors
- Buyers are all mega-passive institutions, which may limit upside catalyst potential from active advocacy
- Morgan Stanley's position value slightly decreased despite massive share increase, suggesting possible share price decline during the period
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-RDY-2024-Q4 |
Track record
73 reports on RDY
6 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 6 of 11 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers